Australia Moves Closer To Reducing HTA Discount Rate For First Time In Decades
Executive Summary
The pharmaceutical industry body Medicines Australia has welcomed an advisory committee’s recommendation on reducing the 5% discount rate that has been used in health technology assessments for 30 years, although it would have liked to see a bigger reduction and to have it implemented more quickly.
You may also be interested in...
Australian HTA Consults On Discount Rate
PBAC, Australia’s health technology assessment body, is asking for feedback on whether its discount rate – a tool used in economic modelling – is too high.
EU Falsified Medicines Directive ‘Not Working’ In Northern Ireland
Industry representatives told a House of Lords committee about continuing Brexit-related problems such as the extra work involved in checking compliance with the EU Falsified Medicines Directive and the drawbacks of a proposed “dual regulatory regime.”
UK Regulator Says April Fee Rise Will Support 'Innovative & Efficient' Service
The Medicines and Healthcare products Regulatory Agency says that the fee increases to be introduced on 1 April, along with 18 new fees, are necessary for its long-term financial sustainability and its ability to provide a “responsive, innovative and efficient regulatory service.”